ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

Liu, Tong; Liu, Shuang; Guan, Shangwei; Tai, Yu; Jin, Yao; Dong, Mei*哈尔滨医科大学
JOURNAL OF CHEMOTHERAPY2023-11-17DOI: 10.1080/1120009X.2022.2162220
4被引8阅读
引用收藏
分享

摘要

The aim of this study was to assess the cost-effectiveness of pembrolizumab versus chemotherapy for metastatic colorectal cancer (mCRC) patients with mismatch-repair deficiency or microsatellite instability-high (dMMR/MSI-H) in China. A partitioned survival model was constructed to determine the costs and effects of pembrolizumab and chemotherapy based on KEYNOTE-177 trial outcomes data. Health outcomes were measured in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). The Chinese health service system perspective was considered. A willing-to-pay threshold was set at 35,832 USD/QALY, which was three times the gross domestic product (GDP) per capita of China in 2021. We examined the robustness of the model in the one-way and probabilistic sensitivity analysis. Pembrolizumab was associated with better health outcomes than chemotherapy (5.30 vs 3.37 QALYs). Compared with chemotherapy, the pembrolizumab strategy yielded an incremental cost of $16 032.57, which resulted in an ICER of $8285 per QALY. The cost of pembrolizumab and chemotherapy had the largest impact on the ICER. The parameters with less influence on the ICER were utility values of the Post-PFS state. Compared to chemotherapy, pembrolizumab had the economic advantage as the first-line treatment of mCRC patients with dMMR/MSI-H in China.

学科与关键词

关键词
Pembrolizumabchemotherapycolorectal cancermismatch-repair deficiencycost-effectiveness
相关
加载中…
  • Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
    Wu, X.; Mao, Y.; Xu, N.; Bai, Y.; Wang, D.; Chen, X.; Yin, X.; Deng, Y.; Yang, J.; Zhang, J.; Tang, J.; Huang, Y.; Li, J.; Xu, M.; Li, N.; Mao, Y.; Gozman, A.; Xu, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
  • Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
    Mao, Y.; Wu, X.; Xu, N.; Bai, Y.; Wang, D.; Chen, X.; Yin, X.; Deng, Y.; Yang, J.; Zhang, J.; Tang, J.; Huang, Y.; Li, J.; Xu, M.; Li, N.; Mao, Y.; Gozman, A.; Xu, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
  • A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
    Zheng, Zhiwei; Zhu, Gaofeng; Cao, Xueqiong; Cai, Hongfu*; Zhu, Huide*Expert Review of Clinical Pharmacology, 2023, 16(3): 267-273.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
JOURNAL OF CHEMOTHERAPY
发表日期
2023-11-17
卷期
第 35 卷, 第 8 期
页码
745-752
DOI
10.1080/1120009X.2022.2162220
语言
ENGLISH
成果收录
SCIE
资助标注
Haiyan Foundation of Harbin Medical University Cancer Hospital; [JJQN2023-09]

作者

  • L

    Liu, Tong (第一作者)

    harbin med univ

  • L

    Liu, Shuang

    harbin med univ

查看全部 6 位作者收起作者
  • G

    Guan, Shangwei

    harbin med univ

  • T

    Tai, Yu

    harbin med univ

  • J

    Jin, Yao

    harbin med univ

  • D

    Dong, Mei (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417